Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

Por Wingren, S., Stål, O., Nordenskjöld, B.
Publicado em 1994

Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer

Por Lundgren, K, Nordenskjöld, B, Landberg, G
Publicado em 2009

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

Por Stål, O., Carstensen, J., Hatschek, T., Nordenskjöld, B.
Publicado em 1992

p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.

Por Stenmark-Askmalm, M., Stål, O., Olsen, K., Nordenskjöld, B.
Publicado em 1995

DNA content, malignancy grading and prognosis in T1 and T2 oral cavity carcinomas.

Por Tytor, M., Franzén, G., Olofsson, J., Brunk, U., Nordenskjöld, B.
Publicado em 1987

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer

Por Stal, O, Akerberg, L, Nordenskjold, B, Olsson, B, Rutqvist, LE, Skoog, L
Publicado em 2000

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Por Weiner, M., Skoog, L., Fornander, T., Nordenskjöld, B., Sgroi, D. C., Stål, O.
Publicado em 2013

Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia.

Por Skoog, L, Nordenskjöld, B, Ost, A, Andersson, B, Hast, R, Giannoulis, N, Humla, S, Hägerström, T, Reizenstein, P
Publicado em 1981

Prognostic significance of terminal transferase activity and glucocorticoid receptor levels in acute myeloid leukemia.

Por Skoog, L., Ost, A., Biberfeld, P., Christensson, B., Hast, R., Lagerlöf, B., Nordenskjöld, B., Reizenstein, P.
Publicado em 1984

A pilot study on risk factors and p53 gene expression in colorectal cancer.

Por Fredrikson, M., Axelson, O., Sun, X. F., Arbman, G., Nilsson, E., Nordenskjöld, B., Sjödahl, R., Söderkvist, P.
Publicado em 1996

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

Por Stål, O., Skoog, L., Rutqvist, L. E., Carstensen, J. M., Wingren, S., Sullivan, S., Andersson, A. C., Dufmats, M., Nordenskjöld, B.
Publicado em 1994

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Por Jirström, K, Rydén, L, Anagnostaki, L, Nordenskjöld, B, Stål, O, Thorstenson, S, Chebil, G, Jönsson, P-E, Fernö, M, Landberg, G
Publicado em 2005

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

Por Rosell, J, Nordenskjöld, B, Bengtsson, N-O, Fornander, T, Hatschek, T, Lindman, H, Malmström, P-O, Wallgren, A, Stål, O, Carstensen, J
Publicado em 2011

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

Por Jerevall, P-L, Ma, X-J, Li, H, Salunga, R, Kesty, N C, Erlander, M G, Sgroi, D C, Holmlund, B, Skoog, L, Fornander, T, Nordenskjöld, B, Stål, O
Publicado em 2011

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-...

Por Pestalozzi, B. C., Francis, P., Quinaux, E., Dolci, S., Azambuja, E., Gelber, R. D., Viale, G., Balil, A., Andersson, M., Nordenskjöld, B., Gnant, M., Gutierrez, J., Láng, I., Crown, J. P. A., Piccart-Gebhart, M.
Publicado em 2008